Gilead Sciences, Inc. announced that Ted Love, MD, has been appointed to the company?s Board of Directors. Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics. Previously, he was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. where he led the company from a pre-clinical startup to a global commercial company with a focus on sickle cell disease.

Prior, he was Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc.; President, Chief Executive Officer and Chairman of Nuvelo, Inc.; and Senior Vice President, Development at Theravance Biopharma, Inc. He began his biotech career at Genentech. Dr. Love earned his MD from the Yale School of Medicine and completed a residency in Internal Medicine and a fellowship in cardiology at Massachusetts General Hospital. Known for championing access to care, Dr. Love received the William E. Proudford Sickle Cell Fund 2023 Distinguished Service Award for addressing ongoing healthcare disparities facing the sickle cell disease community.

In 2023, he also earned the Spirit of the Heart Health Equity Champion Award from the Association of Black Cardiologists. The Board also selected Dr. Love to serve on the Audit Committee of the Board, effective immediately upon the conclusion of the 2024 Annual Meeting of Stockholders (the ?2024 Annual Meeting?), subject to his re-election as a director by the Company?s stockholders at such meeting.